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Hazardous drugs are associated with causing acute and chronic side effects to
healthcare workers that experience occupational exposures. Antineoplastic
drugs are known to cause headaches, nausea, vomiting, hair loss, mutagenic
activity, spontaneous abortions, infertility, and congenital malformations.
Currently, there are no acceptable thresholds for exposures to this type of
hazardous drugs. The use of as low as reasonably acceptable (ALARA) is used
for exposures to these types of drugs. Occupational exposure risk should be
evaluated within facilities where they are used. Performing hazardous drug
wipe sampling in areas that are high risk for contamination can provide
information to facilities on how to protect their employees.

Introduction and Background

A

ntineoplastic drugs are a workplace hazard. These drugs are known to be toxic to cells that are
non-cancerous (Vyas, Yiannakis, Turner and Sewell, 2013). These types of drugs are
associated with adverse side effects for employees with both acute and chronic exposures.
Some of the earliest reports of these drugs posing occupational risks was in 1979 (Soteriades et al.,
2020). The levels were quantifiable in the urine of nurses handling these mutagenic drugs. Previously,
the worker exposures were higher levels (e.g., mg/mL) and currently the exposures are much lower.
Most exposures recently are nanograms per milliliter (ng/mL) (Soteriades et al., 2020). Since the
1940‟s, the toxicity of cancer treatments has been known to cause side-effects to both patients and to
the healthcare workers handling these drugs while performing their daily duties (Soteriades et al.,
2020). Because healthcare workers handle these toxic drugs, the occupational risk should be evaluated.
The symptoms associated with occupational exposure to Antineoplastic drugs include headaches,
nausea, vomiting, hair loss, hypersensitivity, mutagenic activity, spontaneous abortions, infertility, and
congenital malformations (Vyas, Yiannakis, Turner and Sewell, 2013). These symptoms have been
reported in healthcare workers that are being exposed to these cytotoxic drugs at much lower doses
than patients (Dugheri et al, 2018). The drugs are also known to cause irritation and/or damage to the
skin, eyes, and mucous membranes. In another study, it was been shown that the compounds were
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mutagenic to mammalian cells in cell cultures (Harrison, Peters, and Bing, 2006). Antineoplastics have
no therapeutic relevance to individuals that do not require these types of drug therapies.
By 2020, it was expected that there will be a rise in yearly cancer diagnoses to 16 million, globally
(Dugheri et al., 2018). The market for cancer treatment drugs is expected to generate approximately US
$161.3B by the end of 2021. Treatments included in the estimate are chemotherapy, hormone therapy,
immunotherapy, and targeted therapy, with chemotherapy projected to be 50% of the revenue.
Antineoplastic drugs are classified as hazardous chemicals by National Institute for Occupational
Safety and Health (NIOSH) (Dugheri et al., 2018).
NIOSH published the Preventing Occupational Exposures to Antineoplastic and Other Hazardous
Drugs in Health Care Settings Alert in 2004. The list was recently updated in May 2020 to include
newly approved drugs by the Food and Drug Administration (NIOSH, 2020). Of the drugs on this list
from NIOSH, roughly half of them are antineoplastics. The purpose of this alert was to bring awareness
to employees the risk involved with the handling of these drugs and outline protective measures they
could implement for their facility (Fuller, Bain, Sperrazza, and Mazzuckelli, 2007).
Currently, there is no safe occupational threshold, such as a Permissible Exposure Limit (PEL), for
hazardous drugs, however, there have been proposals for possible threshold limits for single drugs only
(NIOSH, 2020). Healthcare facilities are trying to minimize the occupational exposure by utilizing the
NIOSH hierarchy of controls, by implementing engineering controls, administrative controls and
personal protective equipment, as well as environmental monitoring (i.e. wipe sampling) and biological
monitoring (laboratory testing) as a method to identify problems and create more worker awareness
(Dugheri et al., 2018).
The occupational exposure to hazardous drugs by healthcare workers is proposed to happen most
commonly by dermal contact. It is not likely that healthcare workers are exposed via inhalation of the
hazardous drugs. Hazardous drugs that have a low molecular weight (< 500 Daltons) are of concern
because these drugs are easily absorbed through the skin, whereas some of the current hazardous drugs
have a molecular weight of >40,000 Daltons (Conner and Smith, 2016; Connor, Zock and Snow,
2016).
The larger molecular weight limits the dermal uptake from contaminated surfaces. However, nurses
have a higher risk of exposure and possible dermal uptake of these higher molecular weight drugs due
to constant hand-washing practices, which damages their skin and causes cracks that these drugs can
penetrate through (Conner and Smith, 2016; Connor, Zock and Snow, 2016).
Wipe sampling is one of the most common practices for hazardous drug contamination assessment
(Conner and Smith, 2016; Connor, Zock and Snow, 2016). Environmental monitoring has shown that
hazardous drugs can be found in the air and on work surfaces in sterile compounding rooms,
manufacturing and packaging areas for the compounded sterile products and clinical administration
areas (Harrison, Peters, and Bing, 2006). Performing hazardous drug wipe sampling in areas at risk for
exposure can provide information for environmental monitoring on cleaning processes and handling of
hazardous materials.
Environmental wipe sampling has been used for the last 20 years in healthcare facilities to evaluate
contamination within the workplace. Conner, Zock and Snow (2016) stated that other reasons for
surface sampling is as follows: hazard identification and evaluation, exposure assessment, facility
characterization, housekeeping, selection of engineering controls, evaluation of engineering and
administrative/work practice controls, evaluation of exposure pathways, selection of personal
protective equipment, compliance with regulations and standards, source identification, education and
training, and investigation of complaints. The samples that were collected in the facilities of were not
https://doi.org/10.6084/m9.figshare.14740761
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used for worker exposure but to look at the environmental contamination as a possibility for worker
exposure (Conner and Smith, 2016; Connor, Zock and Snow, 2016).

Recommended Wipe Sampling Methods
Wipe sampling was originally developed to evaluate other agents such as lead, asbestos,
methamphetamine, and antibiotics (Connor and Smith, 2016; Connor, Zock and Snow, 2016). This
methodology was evaluated and applied to hazardous drugs. However, not all hazardous drugs can be
analyzed because not all drugs have methods designed to analyze them in a laboratory. Additional
methods can be developed for other drugs that do not currently have a testing method determined, as
long as there are antibodies available for the drug (Conner and Smith, 2016; Connor, Zock and Snow,
2016).
When performing hazardous wipe sampling, there is a need to have a strategy in mind for which factors
are to be assessed and what variables may be present in the sampling evaluation. Some factors to
consider are the types of hazardous drugs that are being used and quantities stored and used within the
facility. Once a sampling plan has been completed, a certified laboratory and/or industrial hygiene
professional that conducts this type of sampling should be identified. Currently, there are no standards
for sampling and analysis for these drugs, therefore it is essential to identify a laboratory that is
experienced with hazardous drug wipe sampling analysis (Power, Sessink, Gesy, and Charbonneau,
2014). The laboratory should have a validation process for the drugs their facility evaluates. These
validation methods should include how samples are stored for stability, medium desorption efficiency,
limits of detection and quantitation, calibration curves and quality control methods. Their method
should give greater than 90% extraction efficiency, which is preferred, however greater than 75%
extraction is acceptable (Conner & Smith, 2016).
When hazardous drug wipe sampling is performed, the sample size should be no less than 100 cm 2,
however if a smaller sample size is used, more samples must be taken which can increase the cost of
this testing since the cost is per wipe rather than per drug being tested for. A more acceptable size
would be 400 cm2, which would give a larger sampling area and reduce the cost by not needing as
many samples for one location. A sampling plan should be devised so that the facility knows exactly
what locations were sampled and make note of what type of activity takes place in those locations (i.e.,
surface of the biological safety cabinet – admixing of hazardous drugs). Common locations for
hazardous drug wipe sampling would be the geometric center of the engineering controls (biological
safety cabinet or compounding aseptic containment isolator), where the direct compounding area is
located. The floors directly below the engineering controls, pass-throughs from the hazardous drug
storage into the negative pressure hazardous drug ISO Class 7 buffer areas and the pass through from
the hazardous buffer areas to the general pharmacy, equipment, counters, storage containers, door
handles, high touch areas, and computer keyboards (Conner and Smith, 2016; Connor, Zock and Snow,
2016).
Once the sampling has been completed, samples are sent overnight to a laboratory where the samples
are processed and analyzed. Typical methods used for specimen recovery and analysis are gas
chromatography, liquid chromatography, high-performance liquid chromatography, ultra-highperformance liquid chromatography along with mass spectrometry, tandem mass spectrometry or
inductively coupled plasma mass spectrometry. These methods determine the concentration of
hazardous drugs present on the wipe samples that have been collected within the healthcare facility
(Conner and Smith, 2016; Connor, Zock and Snow, 2016).
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Summary and Conclusions
Currently, no standards or regulations exist for an acceptable level of exposure to hazardous drug, and
nothing is known about the synergistic effects multiple drugs could elicit in human systems. The only
allowable standard for exposure is as low as reasonably achievable (ALARA). A common approach is
put in place workplace controls, as well as implementation of personnel training on the handling of
hazardous drugs, cleaning, deactivation and decontamination of work surfaces and surveys given to
healthcare staff involved with the processes of admixture and administration of these therapies could
work to lower potential contamination and the exposure of employees to these toxic drugs in the
workplace (Soteriades, et al., 2020). Despite the usual healthcare protocols, workers may not be fully
protected in their facilities. The overwhelming evidence is that an occupational risk persists for those
handing antineoplastic drugs. The highest risk groups include pharmacists and their team that
compounds antineoplastic drugs and the nursing staff that administers these drugs to patients (Vyas,
Yiannakis, Turner and Sewell, 2013). Surface sampling should be used as part of an environmental
monitoring program. In doing so, results will inform staff the larger picture of possible contamination
and exposures on within the facility (Conner and Smith, 2016; Connor, Zock and Snow, 2016).
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